Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been given an average recommendation of “Buy” by the ten ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.83.

Several equities analysts recently issued reports on the company. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective on the stock in a research note on Tuesday, January 23rd. Needham & Company LLC raised their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Friday, December 1st. Finally, BMO Capital Markets raised their price objective on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a research note on Friday, November 10th.

Amphastar Pharmaceuticals (NASDAQ AMPH) traded down $0.09 during mid-day trading on Tuesday, hitting $18.41. 129,168 shares of the stock were exchanged, compared to its average volume of 175,106. Amphastar Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $19.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The firm has a market capitalization of $848.25, a P/E ratio of 122.67, a P/E/G ratio of 1.29 and a beta of 1.51.

In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $18.04, for a total value of $141,830.48. Following the sale, the director now directly owns 31,978 shares in the company, valued at $576,883.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 6,226 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. Insiders have sold 75,443 shares of company stock worth $1,434,441 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the business. Teacher Retirement System of Texas bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $242,000. Municipal Employees Retirement System of Michigan lifted its stake in Amphastar Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after buying an additional 4,960 shares during the last quarter. SG Americas Securities LLC lifted its stake in Amphastar Pharmaceuticals by 164.7% in the third quarter. SG Americas Securities LLC now owns 16,385 shares of the company’s stock valued at $293,000 after buying an additional 10,195 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Amphastar Pharmaceuticals by 70.2% in the third quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock valued at $321,000 after buying an additional 7,401 shares during the last quarter. Finally, Thrivent Financial For Lutherans lifted its stake in Amphastar Pharmaceuticals by 7.2% in the second quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after buying an additional 1,460 shares during the last quarter. Institutional investors own 43.85% of the company’s stock.

WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of “Buy” from Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/13/amphastar-pharmaceuticals-inc-amph-receives-consensus-recommendation-of-buy-from-analysts.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply